Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II

被引:26
作者
Miller, R. [1 ]
机构
[1] Univ Otago, Sch Med Sci, Dept Anat & Struct Biol, OCTSPAN, Dunedin, New Zealand
关键词
Antipsychotic drugs; neuroleptic drugs; cholinergic interneurones; D1; receptors; D2; muscarinic M1 receptors; muscarinic M4 receptors; neuroleptic threshold; individualized dose; atypical antipsychotic agents; PLASMA HALOPERIDOL LEVELS; INDUCED SUPERSENSITIVITY PSYCHOSIS; D2-DOPAMINE RECEPTOR OCCUPANCY; ABRUPT CLOZAPINE WITHDRAWAL; DOPA-INDUCED DYSKINESIAS; CLINICAL-RESPONSE; SCHIZOPHRENIC-PATIENTS; PARKINSONS-DISEASE; ATYPICAL ANTIPSYCHOTICS; SCHIZOAFFECTIVE DISORDER;
D O I
10.2174/157015909790031184
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haase's "neuroleptic threshold" concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp "all-or-none" threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.
引用
收藏
页码:315 / 330
页数:16
相关论文
共 138 条
[41]  
Friedman JH, 2000, MOVEMENT DISORD, V15, P201, DOI 10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO
[42]  
2-D
[43]  
Friedman JH, 1998, CLIN NEUROPHARMACOL, V21, P285
[44]   Switching between clozapine and risperidone treatment [J].
Gardner, DM ;
Baldessarini, RJ ;
Benzo, J ;
Zarate, CA ;
Tohen, M .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 (04) :430-431
[45]   TREATMENT WITH MESORIDAZINE AND THIORIDAZINE IN CHRONIC-SCHIZOPHRENIA .1. ASSESSMENT OF CLINICAL AND ELECTROPHYSIOLOGIC RESPONSES IN REFRACTORY HALLUCINATING SCHIZOPHRENICS [J].
GARDOS, G ;
TECCE, JJ ;
HARTMANN, E ;
BOWERS, P ;
COLE, JO .
COMPREHENSIVE PSYCHIATRY, 1978, 19 (06) :517-525
[46]  
GARVER DL, 1984, J CLIN PSYCHOPHARM, V4, P133
[47]  
GARVER DL, 1977, AM J PSYCHIAT, V134, P304
[48]   SINGLE PHOTON-EMISSION TOMOGRAPHY ASSESSMENT OF CEREBRAL DOPAMINE D2 RECEPTOR BLOCKADE IN SCHIZOPHRENIA [J].
GEANEY, DP ;
ELLIS, PM ;
SOPER, N ;
SHEPSTONE, BJ ;
COWEN, PJ .
BIOLOGICAL PSYCHIATRY, 1992, 32 (03) :293-295
[49]   D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia:: a PET study [J].
Gefvert, O ;
Lundberg, T ;
Wieselgren, IM ;
Bergström, M ;
Långström, B ;
Wiesel, FA ;
Lindström, L .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 (02) :105-110
[50]  
GONIER T, 1970, BEHAV NEUROPSYCHIATRY, V2, P47